Benkert, Pascal

Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis

Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 1,164

Serum neurofilament light levels in normal aging and their association with morphologic brain changes

Khalil, M., Pirpamer, L., Hofer, E., Voortman, M. M., Barro, C., Leppert, D., Benkert, P., Ropele, S., Enzinger, C., Fazekas, F., et al. (2020) · Nature Communications

Dementia and Cognitive Impairment ResearchCerebrovascular and genetic disorders

Cited by 572

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 517

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Meier, S., Willemse, E. A. J., Schaedelin, S., Oechtering, J., Lorscheider, J., Melie-Garcia, L., Cagol, A., Barakovic, M., Galbusera, R., Subramaniam, S., et al. (2023) · JAMA Neurology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 289

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

Cantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., et al. (2019) · JAMA Neurology

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 199

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

Disanto, G., Benkert, P., Lorscheider, J., Mueller, S., Vehoff, J., Zecca, C., Ramseier, S., Achtnichts, L., Findling, O., Nedeltchev, K., et al. (2016) · PLOS ONE

Multiple Sclerosis Research StudiesPolyomavirus and related diseases

Cited by 76

Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study

Montalban, X., Piasecka-Stryczynska, K., Kuhle, J., Benkert, P., Arnold, D. L., Weber, M. S., Seitzinger, A., Guehring, H., Shaw, J., Tomic, D., et al. (2024) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesChronic Lymphocytic Leukemia Research

Cited by 21